Flucytosine doses should be adjusted to renal status. Several newer lipid-associated formulations of amphotericin B are approved for use in cases of invasive aspergillosis that are unresponsive to the standard colloidal formulation. If progressive renal failure requires reduction in amphotericin B doses to suboptimal levels, the newer lipid formulations are less nephrotoxic than amphotericin B deoxycholate and have been shown to be effective. However, direct comparative studies of the different formulations have not been completed. Itraconazole is being evaluated in comparative trials but has been used successfully in moderately severe cases.
Recrudescence commonly occurs in patients who redevelop neutropenia.
All rights reserved.